Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma

Zhang, Xue; Wakabayashi, Hiroshi; Hiromasa, Tomo; Kayano, Daiki; Kinuya, Seigo

doi:10.1053/j.semnuclmed.2022.12.005

Cited by 8 publications

(2 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been clinical studies demonstrating the effectiveness of both HSA and LSA [ 131 I]mIBG as a therapeutic agent since the 1980s, and it has received approval in both the US and Europe [ 162 ]. However, there have been only limited randomized controlled trials and its availability has often been problematic, which has hindered its clinical use for the benefit of [ 177 Lu]Lu-DOTATATE, that has replaced it in some indications [ 157 , 163 ].…”

Section: Radioligand Therapy (Rlt)mentioning

confidence: 99%

Clinical Advances and Perspectives in Targeted Radionuclide Therapy

Lepareur,

Ramée,

Mougin-Degraef

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine subspecialty. For many decades, treatment with radionuclides has been mainly restricted to the use of iodine-131 in thyroid disorders. Currently, radiopharmaceuticals, consisting of a radionuclide coupled to a vector that binds to a desired biological target with high specificity, are being developed. The objective is to be as selective as possible at the tumor level, while limiting the dose received at the healthy tissue level. In recent years, a better understanding of molecular mechanisms of cancer, as well as the appearance of innovative targeting agents (antibodies, peptides, and small molecules) and the availability of new radioisotopes, have enabled considerable advances in the field of vectorized internal radiotherapy with a better therapeutic efficacy, radiation safety and personalized treatments. For instance, targeting the tumor microenvironment, instead of the cancer cells, now appears particularly attractive. Several radiopharmaceuticals for therapeutic targeting have shown clinical value in several types of tumors and have been or will soon be approved and authorized for clinical use. Following their clinical and commercial success, research in that domain is particularly growing, with the clinical pipeline appearing as a promising target. This review aims to provide an overview of current research on targeting radionuclide therapy.

show abstract

Section: Radioligand Therapy (Rlt)mentioning

confidence: 99%

Clinical Advances and Perspectives in Targeted Radionuclide Therapy

Lepareur,

Ramée,

Mougin-Degraef

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…In this regard, norepinephrine transporter, a transmembrane protein responsible for reuptake of norepinephrine in synaptic nerve, historically represents the "star target" in the field. Iodine-123-labeled meta-iodobenzylguanidine ([ 123 I]-mIBG), a synthetic analog of norepinephrine, has been widely employed for NCT detection, staging and follow-up, while its therapeutic counterpart ([ 131 I]-mIBG) has been successfully applied in several clinical trials with good results [5].…”

mentioning

confidence: 99%